Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America
Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com
Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma
October 3rd 2018

FDA Approves Once-Weekly Dose of Kyprolis for R/R Multiple Myeloma

Laura Joszt, MA
A once-weekly dose of carfilzomib (Kyprolis) in combination with dexamethasone has been approved to treat patients with relapsed or refractory (R/R) multiple myeloma. The approved regimen improved progression-free survival and had a better overall response rate than a twice-weekly regimen.
Employers Take a Vested Interest in Healthcare
October 3rd 2018

Employers Take a Vested Interest in Healthcare

Employers may not look forward to purchasing healthcare, but they are in the position to transform the market. More employers are getting more involved in healthcare by championing alternative payment models and other services to their employees.
People Living With HIV Have Higher Risk of First and Second Primary Cancer Incidence
October 2nd 2018

People Living With HIV Have Higher Risk of First and Second Primary Cancer Incidence

Jaime Rosenberg
A new study has found that people living with HIV are at an increased risk of both first and second primary cancer incidence.
FDA Approves NGS-Based Test That Detects Very Low Levels of Cancer Cells in ALL or MM
October 2nd 2018

FDA Approves NGS-Based Test That Detects Very Low Levels of Cancer Cells in ALL or MM

Laura Joszt, MA
A test that uses next-generation sequencing (NGS) has been approved to detect and monitor minimal residual disease in patients with multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL).
Top 5 AJMC® Articles of September 2018
September 30th 2018

Top 5 AJMC® Articles of September 2018

Here are the top 5 articles for the month of September.
Working Toward CAR T-Cell Treatments With Fewer Side Effects
September 30th 2018

Working Toward CAR T-Cell Treatments With Fewer Side Effects

Mary Caffrey
Loyola University Chicago and Loyola Medicine announced plans this week to develop their own chimeric antigen receptor T-cells that would have less toxic side effects.
Lack of Discussion Around Cancer Treatment Costs Leads to Financial Toxicity
September 29th 2018

Lack of Discussion Around Cancer Treatment Costs Leads to Financial Toxicity

Samantha DiGrande
Earlier this week, 3 studies were released that investigated the financial difficulties seen in patients living with cancer. Such difficulties are referred to as “financial toxicity,” which was studied in patients with metastatic breast cancer and older patients, as well as the conversations about cost of care that women with breast cancer have with their physicians.
Imfinzi Plus Chemotherapy Reduced Risk of Death by One-Third in Stage III NSCLC
September 28th 2018

Imfinzi Plus Chemotherapy Reduced Risk of Death by One-Third in Stage III NSCLC

Samantha DiGrande
Earlier this week, drug manufacturer Astrazeneca announced the results from a phase 3 trial studying durvalumab (Imfinzi) among patients with stage III unresectable non­–small cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy.
The Risk of Creating Healthcare Monopolies
September 26th 2018

The Risk of Creating Healthcare Monopolies

Burnout and Resilience Among Oncologists
September 26th 2018

Burnout and Resilience Among Oncologists

Healthcare Payment Models
September 26th 2018

Healthcare Payment Models

Oncology Care Within Integrated Delivery Networks
September 26th 2018

Oncology Care Within Integrated Delivery Networks

The Unique Case of the VA Model
September 26th 2018

The Unique Case of the VA Model

Best-in-Class Healthcare Delivery Models
September 26th 2018

Best-in-Class Healthcare Delivery Models

Integrated Delivery Networks
September 26th 2018

Integrated Delivery Networks

The Role of Medium-Sized Employers
September 26th 2018

The Role of Medium-Sized Employers

Large Employers and Healthcare Consolidation
September 26th 2018

Large Employers and Healthcare Consolidation

The Impact of Consolidation on Healthcare Stakeholders
September 26th 2018

The Impact of Consolidation on Healthcare Stakeholders

Potential Benefits of Healthcare Consolidation
September 26th 2018

Potential Benefits of Healthcare Consolidation

Factors Behind Healthcare Consolidation
September 26th 2018

Factors Behind Healthcare Consolidation

The Advent of Managed Care
September 26th 2018

The Advent of Managed Care

History of Mergers and Acquisitions in the Healthcare Industry
September 26th 2018

History of Mergers and Acquisitions in the Healthcare Industry

Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer
September 23rd 2018

Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer

Laura Joszt, MA
With cancer costs rising and patients with cancer disproportionately facing financial toxicity, alternative payment and care delivery models are thought to help alleviate some of the cost burden. However, a review finds limited evidence available to evaluate the efficacy of alternative payment and care models in cancer care.
Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News
September 22nd 2018

Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit
September 22nd 2018

Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit

Jaime Rosenberg
The flagship event of more than 450 Biden Cancer Community Summits convening throughout the day is focusing on sharing experiences, promoting new solutions, and bridging gaps in cancer care.
More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma
September 21st 2018

More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma

Samantha DiGrande
Although many different treatments exist for basal cell carcinoma (BCC), many methods have not been compared in head-to-head randomized trials. A review recently published in Annals of Internal Medicine looked to evaluate the comparative effectiveness and safety of treatments in adults with BCC.
This Week in Managed Care: September 21, 2018
September 21st 2018

This Week in Managed Care: September 21, 2018

This week, the top managed care news included the Senate overwhelmingly voting to ban pharmacist gag clauses; a study found the current vaccine pipeline for HIV, tuberculosis, and malaria may fall short; an expert noted a trend of healthcare cost data seeping into nonhealthcare companies’ earnings calls.
Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma
September 20th 2018

Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma

David Bai
Amgen’s pipeline drug AMG 420, a bispecific T-cell engager (BiTE) for the treatment of patients with relapsing/refractory multiple myeloma (RRMM), has found positive preliminary results in a phase 1 trial.
Dr Denalee O'Malley Highlights Gaps in Cancer Treatment Communication
September 19th 2018

Dr Denalee O'Malley Highlights Gaps in Cancer Treatment Communication

Assessing a patient’s understanding of his or her own illness is important as cancer treatments become more and more complex, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.
A Multidisciplinary Approach to Managing Complexities in Cancer Care
September 19th 2018

A Multidisciplinary Approach to Managing Complexities in Cancer Care

As September marks National Ovarian Cancer Awareness Month, we sat down with ovarian cancer survivor Marion Roth and Vaagn Andikyan, MD, gynecologic oncologist, Western Connecticut Health Network, to discuss Marion's cancer journey and the importance of a multidisciplinary care team in treating complexities in cancer care.
<1
...
363738394041424344
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo